Giant Mucinous Carcinoma of the Breast

Sara Alothman¹, Saqib Saeed¹, Khuram Khan¹, Alexius Ramcharan¹, Hector DePaz¹

1. Surgery, Harlem Hospital Center, New York, USA

Corresponding author: Sara Alothman, sara.k.alothman@gmail.com

---

Abstract

We report a case of giant mucinous carcinoma of the breast in a 55-year-old female who presented with left breast lump for two years. The patient did not seek any medical attention for two years. On exam, the lump measured 12 x 14 cm. Core needle biopsy showed invasive mucinous adenocarcinoma without ductal component. The patient underwent neo-adjuvant chemotherapy without any response. She underwent left modified radical mastectomy. All lymph nodes were negative. This was followed by adjuvant chemotherapy. Mucinous carcinoma is a rare type of breast cancer that carries a good prognosis compared to other types of breast cancers. In this report, we presented a giant mucinous carcinoma measuring 14 cm.

Categories: General Surgery, Oncology

Keywords: giant, breast cancer, mucinous carcinoma of the breast

Introduction

Mucinous carcinoma of the breast is a rare type of breast cancer that represents 1–4% of all breast cancers [1]. The natural history of mucinous carcinoma of the breast is not well known. It is characterized by high mucin to epithelium ratio [2]. Mucinous carcinoma carries a favorable prognosis compared to other types of breast cancer and it tends to occur in older patients [3]. We present a case of giant, locally advanced mucinous carcinoma of the breast, non-responsive to neo-adjuvant chemotherapy treated with surgery.

Case Presentation

A 55-year-old female with no family history of breast cancer presented to breast clinic for evaluation of left breast lump that she noticed two years ago. Initially the lump was painless but recently became symptomatic. Examination revealed a large left breast mass measuring 14 cm x 12 cm involving the medial upper quadrant with overlying skin erythema (Figures 1, 2).

FIGURE 1: Left breast mass.

Received 10/04/2018
Review began 10/31/2018
Review ended 11/12/2018
Published 11/17/2018

© Copyright 2018

Alothman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Alothman S, Saeed S, Khan K, et al. (November 17, 2018) Giant Mucinous Carcinoma of the Breast. Cureus 10(11): e3606. DOI 10.7759/cureus.3606

FIGURE 2: Left breast giant mucinous carcinoma.

Axillary lymph nodes were not palpable. Right breast exam was within normal limits. Ultrasound confirmed the physical exam findings. Core needle biopsy was performed which came back positive for invasive mucinous carcinoma.

The patient was started on neo-adjuvant chemotherapy. After multiple cycles of chemotherapy, the tumor did not show any regression. With no response to neo-adjuvant chemotherapy, decision was made to proceed with left modified radical mastectomy (Figures [3](#), [4](#)).

FIGURE 3: Left breast specimen.

FIGURE 4: Left breast specimen.

Surgical pathology showed resected margins to be free of tumor (Figure 5). All the lymph nodes were negative of carcinoma. The tumor was ER/PR positive and HER2/neu negative and was staged T3N0M0. The patient did well after the surgery. She received adjuvant chemotherapy and started on aromatase inhibitor.

FIGURE 5: Mucinous breast carcinoma. Clumps of tumor cells lie within pools of mucin, without apparent fibrous reaction.

Discussion

The World Health Organization (WHO) defined mucinous carcinoma of the breast as a carcinoma containing a large amount of extracellular epithelial mucus, enough to be visible grossly, and recognizable microscopically surrounding and within tumor cells. It is also named colloid, gelatinous, mucus and mucin adenocarcinoma [3]. It tends to occur at an older age and carries a better prognosis compared to other breast cancer types [4]. It is classified morphologically into two types: pure mucinous carcinoma and mixed mucinous carcinoma, depending on the absence or presence of concomitant areas with typical infiltrating ductal carcinoma. This distinction is important as the pure type has more favorable prognosis than the mixed type [4].

Researchers proposed reasons for favorable prognosis of mucinous breast carcinoma, giving credit to low cellular burden with abundant mucin creating a barrier for the cells from invading the stroma [4].

Patients usually present with a palpable mass but a substantial proportion present with abnormal mammogram with poorly defined or lobulated mass with rare calcifications [5,6]. 20% are mammographically occult [7].

On examination, mucinous carcinomas are generally well-circumscribed and soft. Mucinous carcinomas with high amounts of fibrous stroma are firmer in consistency. A wide range of sizes has been reported in the literature, with an average of approximately 3 cm. Our patient presented with a size of 14 cm.

In our case, the patient had pure mucinous carcinoma. She received neo-adjuvant chemotherapy without clinical response. This is seen in pure mucinous type, where large amount of mucin overestimate the real quantity of tumor cells leading to false interpretation of poor clinical response even though a pathological response is present as presented by Yamaguchi et al. [8]. Therefore, patients with locally advanced tumor are good candidates for primary surgery.

Conclusions

Pure mucinous carcinoma of the breast carries a favorable prognosis than other types of breast cancer. Lymph node involvement is rare. Neo-adjuvant chemotherapy might fail to shrink the tumor. Primary surgery should be considered as first line therapy in locally advanced cases as clinical response is misleading given high mucin to cell ratio in the tumor.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Tsoukalas N, Kiakou M, Tolia M, et al.: Mucinous breast carcinoma with tall columnar cells . *Ann R Coll Surg Engl*. 2018, 100:132-135. [10.1308/rcsann.2018.0060](#)
2. Yoneyama F, Tsuchie K, Sakaguchi K: Massive mucinous carcinoma of the breast untreated for 6 years . *Int J Clin Oncol*. 2003, 8:121-123. [10.1007/s101470300022](#)
3. Azzopardi JG, Chepik OF, Hartmann WH, et al.: The World Health Organization histological typing of breast tumors—second edition. *Am J Clin Pathol*. 1982, 78:806-816. [10.1093/ajcp/78.6.806](#)
4. Toikkanen S, Kujari H: Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. *Hum Pathol*. 1989, 20:758-764. [10.1016/0046-8177\(89\)90069-5](#)
5. Cardenosa G, Doudna C, Eklund GW: Mucinous (colloid) breast cancer: clinical and mammographic findings in 10 patients. *Am J Roentgenol*. 1994, 162:1077-1079. [10.2214/ajr.162.5.8165985](#)
6. Wilson TE, Helvie MA, Oberman HA, Joynt LK: Pure and mixed mucinous carcinoma of the breast: pathologic basis for differences in mammographic appearance. *Am J Roentgenol*. 1995, 165:285-289. [10.2214/ajr.165.2.7618541](#)
7. Lam WWM, Chu WCW, Tse GM, Ma TK: Sonographic appearance of mucinous carcinoma of the breast . *Am J Roentgenol*. 2004, 182:1069-1074. [10.2214/ajr.182.4.1821069](#)
8. Yamaguchi J, Akashi-Tanaka S, Fukutomi T, Kinoshita T, Iwamoto E, Takasugi M: A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. *Breast Cancer*. 2006, 13:100-103. [10.2325/jbcs.13.100](#)